Jupiter Neurosciences has dosed the first patient in RESET, a 30-person Phase 2a trial of JOTROL, a micellar trans-resveratrol formulation, in Parkinson's disease. The study is powered for safety, tolerability and pharmacokinetics — including cerebrospinal fluid levels — with exploratory biomarkers covering energy metabolism and inflammation, not efficacy. The same announcement disclosed that the company has engaged an adviser to evaluate a sale, licensing or other strategic transaction.
Key Points
- Phase 2a tests micellar resveratrol in 30 Parkinson's patients
- Endpoints are safety, tolerability, pharmacokinetics and cerebrospinal fluid exposure
- Company simultaneously exploring sale or licensing of clinical assets
Longevity Analysis
Resveratrol's clinical record has been constrained less by its proposed mechanisms than by poor oral absorption and rapid metabolism, which is precisely what a micellar carrier is designed to address — making this a test of delivery as much as of the molecule. The targeted pathways, mitochondrial dysfunction, oxidative burden and neuroinflammation, sit at the intersection of cellular energy output and immune signaling in neural tissue, the same axis implicated in broader neurodegenerative decline. Measurable cerebrospinal fluid concentrations would be the meaningful readout here, since a compound that never reaches the central nervous system cannot act on it regardless of what consumer formulations claim.
Original published by Longevity.Technology, by Kyle Umipig.